Significant reduction seen in the mean Worst Itch Numeric Rating Scale scores for high-, mid-, low-dose vixarelimab versus placebo

Greater proportion of those receiving nemolizumab monotherapy versus placebo achieved itch response, IGA success
 

Clinical trials show significant benefits for itch, skin nodules, and sleep disturbance versus placebo